Newspaper Publication of extract of Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2026.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech Limited has published its consolidated audited financial results for Q4 FY2026 and the full financial year ended March 31, 2026. For the quarter, total income from operations stood at Rs. 6,848.62 million with net profit after tax of Rs. 459.67 million and EPS of Rs. 8.30 (annualized). For the full year FY2026, total income reached Rs. 23,963.65 million, a significant increase from Rs. 17,520.66 million in FY2025. Net profit after tax for FY2026 was Rs. 1,492.13 million compared to Rs. 1,428.38 million in the previous year. Earnings per share improved to Rs. 26.95 for FY2026 from Rs. 25.84 in FY2025. The results were reviewed by the Audit Committee and approved by the Board of Directors on April 27, 2026.
The company demonstrated solid revenue growth of approximately 37% year-over-year for Q4 and about 37% for the full year, with profit after tax growing at a slower pace of around 4.5% for FY2026, indicating some margin pressure. The improved EPS suggests better per-share profitability despite modest bottom-line growth.